Skip to content
DataLookout
Menu

BIO-ADNCT05099315

Microbiome in Atopic Dermatitis Under Systemic Therapy

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 3 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 31, 2025 to Dec 31, 2026
    • Eligibility criteria expanded, about 4 words
    • Secondary endpoints: details revised at 4 of 6 entries
  2. Minor Study completion date: Dec 31, 2026 to Dec 31, 2025
    • Site details revised
    v4
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Comparison of the microbial composition
Timeframe: 1 year
Comparison of microbial composition of the skin with serological biomarkers
Timeframe: 1 year

Secondary (6)

Microbial composition and skin barrier function
Correlation of main microbial representants of skin microbiome
Correlation of microbiome and severity of atopic dermatitis EASI
Correlation of microbiome and severity of atopic dermatitis SCORAD
Association of the skin microbiome with the mRNA EASI
Show 1 moreShow less
Association of the skin microbiome with the mRNA SCORAD

Arms and interventions

Dupilumab treated Patients (observational)

Patients with atopic dermatitis with indication for dupilumab treatment will be observed.

Cyclosporine treated Patients (observational)

Patients with atopic dermatitis with indication for cyclosporine treatment will be observed.

Baricitinib treated Patients (observational)

Patients with atopic dermatitis with indication for baricitinib treatment will be observed.

Other: not applicable, observational study

Sites

1 site in 1 country

  • Dpt of Dermatology and Allergology, Charité - Universitätsmedizin BerlinBerlin, State of Berlin, Germany